Dr. Grothey on Trastuzumab for Gastroesophageal Cancer

Axel Grothey, MD
Published: Monday, Nov 07, 2011

Axel Grothey, MD, Professor of Oncology, Consultant, Medical Oncology, Mayo Clinic, discusses the first-line use of the targeted agent trastuzumab (Herceptin) to treat HER2-positive gastroesophageal cancer.

Trastuzumab is the first targeted agent to be used as a first-line therapy in gastroesophageal cancer. All patients with the disease should now be test for an overexpression of HER2. If patients are HER2-positive trastuzumab should be added to the standard chemotherapy, which is usually 5-fluorouracil and platinum agents such as cisplatin.

Axel Grothey, MD, Professor of Oncology, Consultant, Medical Oncology, Mayo Clinic, discusses the first-line use of the targeted agent trastuzumab (Herceptin) to treat HER2-positive gastroesophageal cancer.

Trastuzumab is the first targeted agent to be used as a first-line therapy in gastroesophageal cancer. All patients with the disease should now be test for an overexpression of HER2. If patients are HER2-positive trastuzumab should be added to the standard chemotherapy, which is usually 5-fluorouracil and platinum agents such as cisplatin.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x